Samsung Electronics of Gyeonggi-do, South Korea, has received US Patent No. 6,924,111, "Microarray substrate comprising patterned photoresist film with spot regions, microarray, and method of detecting target material." The patented invention provides a microarray substrate capable of preventing the nonspecific binding of a target material even when a compound such as a blocking material is not used, according to the patent. The patented invention also provides a microarray based on the microarray substrate capable of reducing the nonspecific binding of a target material.
Panomics of Redwood, City, Calif., has received US Patent No. 6,924,113, "Method and kit for isolating DNA probes that bind to activated transcription factors." The patent provides methods, arrays and kits, for identifying and quantifying multiple different activated transcription factors in a biological sample at the same time. In one aspect, according to the patent's abstract, a method is provided for isolating DNA probes that bind to activated transcription factors, including the step of mixing a library of double-stranded DNA probes with a sample containing activated transcription factors. The transcription factor probes that have bound to the activated transcription factors are then isolated from the mixture via an agarose gel separation. The bound probes can be identified by using an array of hybridization probes, the abstract states.
Sigma Genosys of The Woodlands, Tex., has received US Patent No. 6,919,180, "Hybridization rate enhancement for substrate-bound specific nucleic acid-binding agents." The patent describes kits and methods for hybridizing nucleic acids with a specific nucleic acid-binding agent, such as a complementary nucleic acid. The methods described comprise binding a polycationizable attractor compound to the substrate, in addition to the agent. Examples of suitable polycationizable attractor compounds include polypeptides, including those with tunable cationizable amino acid residues, such as histidine, according to the patent's abstract.
Agilent Technologies of Palo Alto, Calif., has received US Patent No. 6,919,181, "Methods for generating ligand arrays." The patent describes methods for producing ligand arrays as well as methods for use of the arrays and kits that include them. According to the patent's abstract, in the subject methods, a substrate having a surface displaying carboxylic ester functional groups that produce surface bound hydroxyl functional groups upon hydrolysis is provided. Next, the functional groups are hydrolyzed to hydroxyl functional groups. The resultant substrate, optionally after an additional functionalization step, is then contacted with ligands, for example via deposition of each different ligand onto a different region of the surface, resulting in covalent attachment of the contacted ligands to the surface.
Agilent has also received US Patent No. 6,919,531, "Methods for producing glass substrates for use in biopolymeric microarrays." The patent describes methods for producing glass substrates having scribed edges, where, in certain embodiments, at least one scribe line is scribed in glass using reduced laser power at the beginning and end of each scribe line relative to the laser power used to scribe the remaining portions of each respective scribe line. The scribed glass is also singulated to produce a plurality of scribed glass pieces, each having straight and smooth ends substantially free of edge protrusions, the patent states. The patentee recommends the glass slides as substrates for printed biopolymeric microarrays.
Affymetrix of Santa Clara, Calif., has received US Patent No. 6,919,211, "Polypeptide arrays." According to the patent, methods useful for de novo sequencing of an unknown polymer sequence, for verification of known sequences, for fingerprinting polymers, and for mapping homologous segments within a sequence are provided. The patentee claims that the present invention is applicable to fingerprinting, mapping, and general screening of specific interactions. Means for automating sequencing are also provided. More specifically, the invention provides a composition comprising a plurality of sequence specific reagents attached to a solid substrate, which reagents are capable of specifically binding to a predetermined subunit sequence of a pre-selected multi-subunit length having at least three subunits. Usually the specific reagents are all attached to a single solid substrate, and the reagents comprise about 3,000 different sequences, the patent states. Usually, the reagents are localized in regions of the substrate having a density of at least 25 regions per cm2, and often the substrate has a surface area of less than about 4 square cm2, the patent states.
Amersham Biosciences, now GE Healthcare, of Uppsala, Sweden has received US Patent No. 6,921,638, "Hydrogel-based microarray signal-amplification methods and devices therefor." The patent describes methods and devices for detecting nucleic acid and protein targets on hydrogel microarrays, where fluorophores are incorporated into the targets and detected. A linear correlation between target concentration and signal amplitude is maintained through the elimination of active enzyme amplification, according to the patent's abstract.